PE powers cancer-focused Neogene’s Series A to $110m

In the latest example of the life science sector's appeal to alt players, T-cell therapy specialist Neogene Therapeutics raised $110 million in a Series A round co-led by private equity firms Jeito Capital and Ecor1 Capital, along with British healthcare trust Syncona.

Neogene's research, which is still in the preclinical stage, aims to identify neoantigen specific T-cell receptor genes that will subsequently be engineered T cell therapies for solid tumors. T cell treatments are part of the cancer immunotherapy . . .

Continue Reading With a Free Trial

Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.

Already a subscriber? Log in.

Related Articles

Back to top button

Get our daily news digest
in your inbox

Our FREE mailing list brings you daily alts intel.

Thank you for subscribing.

Something went wrong.